Entero Therapeutics, Inc. (ENTO)
NASDAQ: ENTO · Real-Time Price · USD
0.4843
+0.0148 (3.15%)
At close: Jun 18, 2025, 4:00 PM
0.4999
+0.0156 (3.22%)
After-hours: Jun 18, 2025, 7:55 PM EDT
Entero Therapeutics Employees
Entero Therapeutics had 2 employees as of December 31, 2024. The number of employees decreased by 7 or -77.78% compared to the previous year.
Employees
2
Change (1Y)
-7
Growth (1Y)
-77.78%
Revenue / Employee
n/a
Profits / Employee
-$12,571,323
Market Cap
2.31M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ENTO News
- 5 days ago - FluroTech Ltd. Announces Change in Directors - Newsfile Corp
- 3 months ago - Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC - Newsfile Corp
- 4 months ago - Entero Therapeutics Appoints Richard Paolone as CEO - GlobeNewsWire
- 4 months ago - Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members - GlobeNewsWire
- 7 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - Accesswire
- 7 months ago - ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO - Business Wire
- 7 months ago - Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company - GlobeNewsWire
- 9 months ago - Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board - Business Wire